Latest Breaking News On - Jacquie ross - Page 1 : comparemela.com

Gilead Sciences, Inc.: Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease - Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research

Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis

FOSTER CITY - Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with.

Gilead Sciences, Inc.: Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy

Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript

Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc.

Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript

GILD earnings call for the period ending March 31, 2024.